192 related articles for article (PubMed ID: 33837851)
1. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.
Arranz-Nicolás J; Martin-Salgado M; Adán-Barrientos I; Liébana R; Del Carmen Moreno-Ortíz M; Leitner J; Steinberger P; Ávila-Flores A; Merida I
Cancer Immunol Immunother; 2021 Nov; 70(11):3277-3289. PubMed ID: 33837851
[TBL] [Abstract][Full Text] [Related]
2. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
Arranz-Nicolás J; Martin-Salgado M; Rodríguez-Rodríguez C; Liébana R; Moreno-Ortiz MC; Leitner J; Steinberger P; Ávila-Flores A; Merida I
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33246984
[TBL] [Abstract][Full Text] [Related]
3. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals.
Arranz-Nicolás J; Ogando J; Soutar D; Arcos-Pérez R; Meraviglia-Crivelli D; Mañes S; Mérida I; Ávila-Flores A
Cancer Immunol Immunother; 2018 Jun; 67(6):965-980. PubMed ID: 29572701
[TBL] [Abstract][Full Text] [Related]
4. Diacylglycerol kinases in cancer.
Mérida I; Torres-Ayuso P; Ávila-Flores A; Arranz-Nicolás J; Andrada E; Tello-Lafoz M; Liébana R; Arcos R
Adv Biol Regul; 2017 Jan; 63():22-31. PubMed ID: 27697466
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade.
Okada N; Sugiyama K; Shichi S; Shirai Y; Goto K; Sakane F; Kitamura H; Taketomi A
Cancer Immunol Immunother; 2022 Apr; 71(4):889-903. PubMed ID: 34482409
[TBL] [Abstract][Full Text] [Related]
6. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
8. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
9. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
Wichroski M; Benci J; Liu SQ; Chupak L; Fang J; Cao C; Wang C; Onorato J; Qiu H; Shan Y; Banas D; Powles R; Locke G; Witt A; Stromko C; Qi H; Zheng X; Martin S; Ding M; Gentles R; Meanwell N; Velaparthi U; Olson R; Wee S; Tenney D; Parker CG; Cravatt BF; Lawrence M; Borzilleri R; Lees E
Sci Transl Med; 2023 Oct; 15(719):eadh1892. PubMed ID: 37878674
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
11. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
13. Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8
Andrada E; Liébana R; Merida I
EBioMedicine; 2017 May; 19():39-48. PubMed ID: 28438506
[TBL] [Abstract][Full Text] [Related]
14. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
15. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
16. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM
mBio; 2021 Feb; 12(1):. PubMed ID: 33531395
[TBL] [Abstract][Full Text] [Related]
17. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1.
Ruffo E; Malacarne V; Larsen SE; Das R; Patrussi L; Wülfing C; Biskup C; Kapnick SM; Verbist K; Tedrick P; Schwartzberg PL; Baldari CT; Rubio I; Nichols KE; Snow AL; Baldanzi G; Graziani A
Sci Transl Med; 2016 Jan; 8(321):321ra7. PubMed ID: 26764158
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.
Purow B
Clin Cancer Res; 2015 Nov; 21(22):5008-12. PubMed ID: 26420856
[TBL] [Abstract][Full Text] [Related]
20. A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response.
Liu K; Kunii N; Sakuma M; Yamaki A; Mizuno S; Sato M; Sakai H; Kado S; Kumagai K; Kojima H; Okabe T; Nagano T; Shirai Y; Sakane F
J Lipid Res; 2016 Mar; 57(3):368-79. PubMed ID: 26768655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
